Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C24H26N4O5S
CAS Number:
Molecular Weight:
482.55
MDL number:
NACRES:
NA.21
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C(N(CC(NC1=CC=C(C=C1)C2=NOC=N2)=O)C3=C(C=CC=C3C)C)C4CCS(CC4)(=O)=O
Application
Amenamevir may be used in laboratory studies to investigate the mechanisms of viral replication, particularly in the context of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It may also be used as a model compound in the development of other antiviral agents, helping researchers understand the structure-activity relationship of helicase-primase inhibitors.
Biochem/physiol Actions
Amenamevir (ASP2151) is an orally active and potent helicase-primase complex inhibitor with equipotency against viral DNA replication of varicella-zoster virus (VZV Ellen EC50/EC90 = 47/460 nM) and herpes simplex virus (EC50/EC90 = 36/230 nM using HSV-1 (KOS) & 28/460 nM using HSV-2 (G)). This antiherpetic agent prevents the replication of these viruses. Amenamevir is much more potent (EC50 38-100 nM) than aciclovir (EC50 = 1.3-2.7 µM) against all VZV strains tested and is active against aciclovir-resistant VZV. This oxadiazolephenyl derivative is 14-times more potent than valaciclovir in a zosteriform-spread model among mice infected with HSV-1 in vivo (EC50 = 1.9 vs. 27 mg/kg, respectively, via twice daily p.o.).
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuko Sato et al.
Antimicrobial agents and chemotherapy, 65(10), e0049421-e0049421 (2021-07-07)
The antiherpetic drug amenamevir (AMNV) inhibits the helicase-primase complex of herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus directly as well as inhibiting the replication of these viruses. Although several mutated HSV viruses resistant to helicase-primase inhibitors have been
Antivirals against Herpes Viruses
Fred Y. Aoki
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 1, 546-562 (2015)
K Shiraki
Drugs of today (Barcelona, Spain : 1998), 53(11), 573-584 (2018-02-17)
Valacyclovir and famciclovir enabled successful systemic therapy for treating herpes simplex virus (HSV) and varicella zoster virus (VZV) infection by their phosphorylation with viral thymidine kinase. Helicase-primase inhibitors (HPIs) inhibit the progression of the replication fork, an initial step in
Kimiyasu Shiraki et al.
Viruses, 13(8) (2021-08-29)
Acyclovir, valacyclovir, and famciclovir are used for the treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Helicase-primase inhibitors (HPIs) inhibit replication fork progression that separates double DNA strands into two single strands during DNA synthesis. The HPIs
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML4173-50MG | 04065272651806 |
| SML4173-10MG | 04065272651790 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service